The drug in question, called vepdegestrant, is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. The phase 3 study ...

Arvinas & Pfizer announce positive topline results from phase 3 VERITAC-2 clinical trial: New Haven, Connecticut Wednesday, March 12, 2025, 10:00 Hrs [IST] Arvinas, Inc., a clinic ...

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically ...

Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, ...

VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically meaningful improvement in progression-free survival - - ...

This suggests that while buyers managed to defend key support at the 20-day Simple Moving Average (SMA), further upside could face resistance unless momentum builds. Looking at support and ...